Lista de obras -

A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors

artículo científico publicado en 2013

APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status

artículo científico publicado en 2010

Advances in understanding prognosis in myeloma

artículo científico publicado en 2016

An unusual case of myocardial infarction

artículo científico publicado en 2010

Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations

artículo científico publicado en 2020

Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma ⬇️

artículo científico publicado en 2016

Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide

artículo científico publicado en 2014

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial

artículo científico publicado en 2015

Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse

artículo científico publicado en 2018

Bortezomib-induced inflammatory neuropathy.

artículo científico publicado en 2010

COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial

artículo científico publicado en 2020

Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy

artículo científico publicado en 2019

Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centres

scientific article published on 28 December 2018

Clinical outcomes and risk factors for severe COVID-19 infection in patients with haematological disorders receiving chemo- or immunotherapy

artículo científico publicado en 2020

Cyclin D type does not influence cell cycle response to DNA damage caused by ionizing radiation in multiple myeloma tumours

artículo científico publicado en 2016

DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation

artículo científico publicado en 2020

Dendritic cells and myeloid leukaemias: plasticity and commitment in cell differentiation.

artículo científico publicado en 2007

Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial

artículo científico publicado en 2020

Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO.

artículo científico publicado en 2010

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.

artículo científico publicado en 2003

Engraftment defect of cytokine-cultured adult human mobilized CD34(+) cells is related to reduced adhesion to bone marrow niche elements

artículo científico publicado en 2012

Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects

artículo científico publicado en 2004

Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma

artículo científico publicado en 2016

Evaluation of the Taguchi methods for the simultaneous assessment of the effects of multiple variables in the tumour microenvironment

artículo científico publicado en 2004

Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016

scientific article published on 22 November 2018

Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.

artículo científico publicado en 2005

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

scientific article published on 22 May 2020

Guidelines for the diagnosis and management of multiple myeloma 2011 ⬇️

artículo científico publicado el 14 de mayo de 2011

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

scientific article published on 01 June 2002

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-l

artículo científico publicado en 2014

Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model.

artículo científico publicado en 2006

Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab

artículo científico publicado en 2004

Influence of cell cycling and cell division on transendothelial migration of CD34+ cells.

artículo científico publicado en 2002

Inherited genetic susceptibility to monoclonal gammopathy of unknown significance

artículo científico publicado en 2014

Insights on Multiple Myeloma Treatment Strategies

artículo científico publicado en 2018

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

artículo científico publicado en 2002

Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma

artículo científico publicado en 2005

Marrow infiltrating regulatory T cells correlate with the presence of dysfunctional CD4+PD-1+ cells and inferior survival in patients with newly diagnosed multiple myeloma

scientific article published on 27 March 2020

Microvasculitic paraproteinaemic polyneuropathy and B-cell lymphoma

artículo científico publicado en 2003

Multiple myeloma and physical activity: a scoping review

artículo científico publicado en 2015

Multiple myeloma: patient outcomes in real-world practice

artículo científico publicado en 2016

Multiple myeloma: practice patterns across Europe

artículo científico publicado en 2016

Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model.

artículo científico publicado en 2015

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

artículo científico publicado en 2002

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

artículo científico publicado en 2014

Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) Trial

artículo científico publicado en 2013

RAS mutation status and bortezomib therapy for relapsed multiple myeloma.

artículo científico publicado en 2015

Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience

artículo científico publicado en 2017

Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity

scientific article published on 01 April 2003

Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality

artículo científico publicado en 2002

Response to 'Impact of immunosuppression on mortality in critically ill COVID-19 patients'

artículo científico publicado en 2020

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma

artículo científico publicado en 2012

Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing

artículo científico publicado en 2016

Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study

artículo científico publicado en 2020

The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary re ⬇️

artículo científico publicado en 2016

The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myeloma

artículo científico publicado en 2014

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial ⬇️

artículo científico publicado en 2016

The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface

artículo científico publicado en 2014

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial

artículo científico publicado en 2019

Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis

scientific article published on 26 January 2020

Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices

artículo científico publicado en 2002

Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response

scientific article published on 21 October 2016

Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction

artículo científico publicado en 2017

Lista de obras de

A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors

APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status

Advances in understanding prognosis in myeloma

An unusual case of myocardial infarction

Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations

Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma ⬇️

Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial

Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse

Bortezomib-induced inflammatory neuropathy.

COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial

Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy

Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centres

Clinical outcomes and risk factors for severe COVID-19 infection in patients with haematological disorders receiving chemo- or immunotherapy

Cyclin D type does not influence cell cycle response to DNA damage caused by ionizing radiation in multiple myeloma tumours

DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation

Dendritic cells and myeloid leukaemias: plasticity and commitment in cell differentiation.

Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial

Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO.

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.

Engraftment defect of cytokine-cultured adult human mobilized CD34(+) cells is related to reduced adhesion to bone marrow niche elements

Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects

Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma

Evaluation of the Taguchi methods for the simultaneous assessment of the effects of multiple variables in the tumour microenvironment

Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016

Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

Guidelines for the diagnosis and management of multiple myeloma 2011 ⬇️

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-l

Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model.

Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab

Influence of cell cycling and cell division on transendothelial migration of CD34+ cells.

Inherited genetic susceptibility to monoclonal gammopathy of unknown significance

Insights on Multiple Myeloma Treatment Strategies

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma

Marrow infiltrating regulatory T cells correlate with the presence of dysfunctional CD4+PD-1+ cells and inferior survival in patients with newly diagnosed multiple myeloma

Microvasculitic paraproteinaemic polyneuropathy and B-cell lymphoma

Multiple myeloma and physical activity: a scoping review

Multiple myeloma: patient outcomes in real-world practice

Multiple myeloma: practice patterns across Europe

Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model.

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) Trial

RAS mutation status and bortezomib therapy for relapsed multiple myeloma.

Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience

Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity

Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality

Response to 'Impact of immunosuppression on mortality in critically ill COVID-19 patients'

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma

Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing

Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study

The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary re ⬇️

The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myeloma

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial ⬇️

The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial

Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis

Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices

Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response

Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction